Concord Biotech announced its unaudited financial results for the second quarter (Q2: Jul-Sep) and half-year ended September 30, 2025. The company reported a profit after tax of ₹62.89 crore for the quarter. The board approved the acquisition of 100% equity share capital of Celliimune Biotech Private Limited and an investment of up to ₹10 crore in a solar power project.
Financial Performance – Q2 2025
Concord Biotech’s standalone unaudited financial results for the second quarter (Q2: Jul-Sep) and half-year ended September 30, 2025, show a solid performance. Key highlights include:
- Revenue from operations: ₹247.06 crore
- Profit before tax: ₹85.52 crore
- Profit after tax: ₹62.89 crore
- Earnings per share: ₹6.01
The company’s total comprehensive income for the quarter stood at ₹84.80 crore.
Strategic Acquisition of Celliimune Biotech
The Board of Directors has approved the acquisition of 100% equity share capital of M/s Celliimune Biotech Private Limited. This related-party transaction aims to expand Concord Biotech’s capabilities in a related sector, with further details to be disclosed upon completion of the acquisition.
Investment in Renewable Energy
To enhance sustainability and reduce energy costs, the Board has approved an investment of up to ₹10 crore in a captive hybrid solar power project for the Limbasi Plant. This project will be executed through an agreement with a relevant party and is aimed at providing a renewable energy source for the plant’s operations.
Source: BSE
